|
1
|
Luo Z, Gao M, Huang N, Wang X, Yang Z,
Yang H, Huang Z and Feng W: Efficient disruption of bcr-abl gene by
CRISPR RNA-guided FokI nucleases depresses the oncogenesis of
chronic myeloid leukemia cells. J Exp Clin Cancer Res. 38:2242019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heaney NB, Pellicano F, Zhang B, Crawford
L, Chu S, Kazmi SM, Allan EK, Jorgensen HG, Irvine AE, Bhatia R and
Holyoake TL: Bortezomib induces apoptosis in primitive chronic
myeloid leukemia cells including LTC-IC and NOD/SCID repopulating
cells. Blood. 115:2241–2250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen SH, Hsieh YY, Tzeng HE, Lin CY, Hsu
KW, Chiang YS, Lin SM, Su MJ, Hsieh WS and Lee CH: ABL genomic
editing sufficiently abolishes oncogenesis of human chronic myeloid
leukemia cells in vitro and in vivo. Cancers (Basel). 12:13992020.
View Article : Google Scholar :
|
|
4
|
Tauer JT, Hofbauer LC, Jung R, Gerdes S,
Glauche I, Erben RG and Suttorp M: Impact of long-term exposure to
the tyrosine kinase inhibitor imatinib on the skeleton of growing
rats. PLoS One. 10:e01311922015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cortes J, Hochhaus A, Hughes T and
Kantarjian H: Front-line and salvage therapies with tyrosine kinase
inhibitors and other treatments in chronic myeloid leukemia. J Clin
Oncol. 29:524–531. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang XY, Zhang XH, Peng L, Liu Z, Yang YX,
He ZX, Dang HW and Zhou SF: Bardoxolone methyl (CDDO-Me or RTA402)
induces cell cycle arrest, apoptosis and autophagy via
PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.
Am J Transl Res. 9:4652–4672. 2017.PubMed/NCBI
|
|
7
|
Fan Z, Luo H, Zhou J, Wang F, Zhang W,
Wang J, Li S, Lai Q, Xu Y, Wang G, et al: Checkpoint kinase1
inhibition and etoposide exhibit a strong synergistic anticancer
effect on chronic myeloid leukemia cell line K562 by impairing
homologous recombination DNA damage repair. Oncol Rep.
44:2152–2164. 2020.PubMed/NCBI
|
|
8
|
Mayoral-Varo V, Jimenez L and Link W: The
critical role of TRIB2 in cancer and therapy resistance. Cancers
(Basel). 13:27012021. View Article : Google Scholar
|
|
9
|
Hou Z, Guo K, Sun X, Hu F, Chen Q, Luo X,
Wang G, Hu J and Sun L: TRIB2 functions as novel oncogene in
colorectal cancer by blocking cellular senescence through AP4/p21
signaling. Mol Cancer. 17:1722018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim HS, Oh SH, Kim JH, Sohn WJ, Kim JY,
Kim DH, Choi SU, Park KM, Ryoo ZY, Park TS and Lee S: TRIB2
regulates the differentiation of MLL-TET1 transduced myeloid
progenitor cells. J Mol Med (Berl). 96:1267–1277. 2018. View Article : Google Scholar
|
|
11
|
Liang Y, Yu D, Perez-Soler R, Klostergaard
J and Zou Y: TRIB2 contributes to cisplatin resistance in small
cell lung cancer. Oncotarget. 8:109596–109608. 2017. View Article : Google Scholar
|
|
12
|
Liu Q, Zhang W, Luo L, Han K, Liu R, Wei S
and Guo X: Long noncoding RNA TUG1 regulates the progression of
colorectal cancer through miR-542-3p/TRIB2 axis and Wnt/β-catenin
pathway. Diagn Pathol. 16:472021. View Article : Google Scholar
|
|
13
|
Link W: Tribbles breaking bad: TRIB2
suppresses FOXO and acts as an oncogenic protein in melanoma.
Biochem Soc Trans. 43:1085–1088. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Zuo J, Wahafu A, Wang MD, Li RC
and Xie WF: Combined elevation of TRIB2 and MAP3K1 indicates poor
prognosis and chemoresistance to temozolomide in glioblastoma. CNS
Neurosci Ther. 26:297–308. 2020. View Article : Google Scholar :
|
|
15
|
Hill R, Madureira PA, Ferreira B, Baptista
I, Machado S, Colaco L, Dos Santos M, Liu N, Dopazo A, Ugurel S, et
al: TRIB2 confers resistance to anti-cancer therapy by activating
the serine/threonine protein kinase AKT. Nat Commun. 8:146872017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang HY, Lin YC, Li J, Huang KY, Shrestha
S, Hong HC, Tang Y, Chen YG, Jin CN, Yu Y, et al: MiRTarBase 2020:
Updates to the experimentally validated microRNA-target interaction
database. Nucleic Acids Res. 48(D1): D148–D154. 2020.
|
|
17
|
Ren D, Yang Q, Dai Y, Guo W, Du H, Song L
and Peng X: Oncogenic miR-210-3p promotes prostate cancer cell EMT
and bone metastasis via NF-ĸB signaling pathway. Mol Cancer.
16:1172017. View Article : Google Scholar
|
|
18
|
Li X, Strietz J, Bleilevens A, Stickeler E
and Maurer J: Chemotherapeutic stress influences
epithelial-mesenchymal transition and stemness in cancer stem cells
of triple-negative breast cancer. Int J Mol Sci. 21:4042020.
View Article : Google Scholar
|
|
19
|
Diaz-Martinez M, Benito-Jardon L, Alonso
L, Koetz-Ploch L, Hernando E and Teixido J: MiR-204-5p and
miR-211-5p contribute to BRAF inhibitor resistance in melanoma.
Cancer Res. 78:1017–1030. 2018. View Article : Google Scholar :
|
|
20
|
Yin J, Zeng A, Zhang Z, Shi Z, Yan W and
You Y: Exosomal transfer of miR-1238 contributes to
temozolomide-resistance in glioblastoma. EBioMedicine. 42:238–251.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Zhou G, Tao F, Cao Y, Han W and Li
Q: circ-ZUFSP regulates trophoblasts migration and invasion through
sponging miR-203 to regulate STOX1 expression. Biochem Biophys Res
Commun. 531:472–479. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tu J, Zhao Z, Xu M, Chen M, Weng Q and Ji
J: LINC00460 promotes hepatocellular carcinoma development through
sponging miR-485-5p to up-regulate PAK1. Biomed Pharmacother.
118:1092132019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Chen J, Sun B, Wu J and Du C:
ONECUT2 accelerates tumor proliferation through activating ROCK1
expression in gastric cancer. Cancer Manag Res. 12:6113–6121. 2020.
View Article : Google Scholar :
|
|
24
|
Racca AC, Prucca CG and Caputto BL: Fra-1
and c-Fos N-Terminal deletion mutants impair breast tumor cell
proliferation by blocking lipid synthesis activation. Front Oncol.
9:5442019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lou Z, Lin W, Zhao H, Jiao X, Wang C, Zhao
H, Liu L, Liu Y, Xie Q, Huang X, et al: Alkaline phosphatase
downregulation promotes lung adenocarcinoma metastasis via the
c-Myc/RhoA axis. Cancer Cell Int. 21:2172021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ban MJ, Byeon HK, Yang YJ, An S, Kim JW,
Kim JH, Kim DH, Yang J, Kee H and Koh YW: Fibroblast growth factor
receptor 3-mediated reactivation of ERK signaling promotes head and
neck squamous cancer cell insensitivity to MEK inhibition. Cancer
Sci. 109:3816–3825. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guilhot F, Druker B, Larson RA, Gathmann
I, So C, Waltzman R and O'Brien SG: High rates of durable response
are achieved with imatinib after treatment with interferon alpha
plus cytarabine: Results from the International randomized study of
interferon and STI571 (IRIS) trial. Haematologica. 94:1669–1675.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ciftci HI, Radwan MO, Ozturk SE, Ulusoy
NG, Sozer E, Ellakwa ED, Ocak Z, Can M, Ali TFS, Abd-Alla IH, et
al: Design, synthesis and biological evaluation of pentacyclic
triterpene derivatives: Optimization of Anti-ABL kinase activity.
Molecules. 24:35352019. View Article : Google Scholar
|
|
29
|
Nardi V, Naveiras O, Azam M and Daley GQ:
ICSBP-mediated immune protection against BCR-ABL-induced leukemia
requires the CCL6 and CCL9 chemokines. Blood. 113:3813–3820. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng S, Shu Y, Lu Y and Sun Y:
Chloroquine Combined with imatinib overcomes imatinib resistance in
gastrointestinal stromal tumors by inhibiting autophagy via the
MAPK/ERK pathway. Onco Targets Ther. 13:6433–6441. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang M, Zeng P, Kang R, Yu Y, Yang L, Tang
D and Cao L: S100A8 contributes to drug resistance by promoting
autophagy in leukemia cells. PLoS One. 9:e972422014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H
and Jia L: Reversal effect of ST6GAL 1 on multidrug resistance in
human leukemia by regulating the PI3K/Akt pathway and the
expression of P-gp and MRP1. PLoS One. 9:e851132014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rome KS, Stein SJ, Kurachi M, Petrovic J,
Schwartz GW, Mack EA, Uljon S, Wu WW, DeHart AG, McClory SE, et al:
Trib1 regulates T cell differentiation during chronic infection by
restraining the effector program. J Exp Med. 217:e201908882020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pulte D, Jansen L and Brenner H: Changes
in long term survival after diagnosis with common hematologic
malignancies in the early 21st century. Blood Cancer J. 10:562020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bernardi S, Malagola M, Zanaglio C,
Polverelli N, Dereli Eke E, D'Adda M, Farina M, Bucelli C, Scaffidi
L, Toffoletti E, et al: Digital PCR improves the quantitation of
DMR and the selection of CML candidates to TKIs discontinuation.
Cancer Med. 8:2041–2055. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guan X, Gu S, Yuan M, Zheng X and Wu J:
MicroRNA-33a-5p overexpression sensitizes triple-negative breast
cancer to doxorubicin by inhibiting eIF5A2 and
epithelial-mesenchymal transition. Oncol Lett. 18:5986–5994.
2019.PubMed/NCBI
|
|
37
|
Meng W, Tai Y, Zhao H, Fu B, Zhang T, Liu
W, Li H, Yang Y, Zhang Q, Feng Y and Chen G: Downregulation of
miR-33a-5p in hepatocellular carcinoma: A possible mechanism for
chemotherapy resistance. Med Sci Monit. 23:1295–1304. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Deng X, Kong F, Li S, Jiang H, Dong L, Xu
X, Zhang X, Yuan H, Xu Y, Chu Y, et al: A KLF4/PiHL/EZH2/HMGA2
regulatory axis and its function in promoting
oxaliplatin-resistance of colorectal cancer. Cell Death Dis.
12:4852021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Han S, Han B, Li Z and Sun D:
Downregulation of long noncoding RNA CRNDE suppresses drug
resistance of liver cancer cells by increasing microRNA-33a
expression and decreasing HMGA2 expression. Cell Cycle.
18:2524–2537. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Metz R, Bannister AJ, Sutherland JA,
Hagemeier C, O'Rourke EC, Cook A, Bravo R and Kouzarides T:
c-Fos-induced activation of a TATA-box-containing promoter involves
direct contact with TATA-box-binding protein. Mol Cell Biol.
14:6021–6029. 1994.PubMed/NCBI
|
|
41
|
Rose M, Burgess JT, O'Byrne K, Richard DJ
and Bolderson E: PARP Inhibitors: Clinical relevance, mechanisms of
action and tumor resistance. Front Cell Dev Biol. 8:5646012020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li T, Li Z, Wan H, Tang X, Wang H, Chai F,
Zhang M and Wang B: Recurrence-associated long non-coding RNA
LNAPPCC facilitates colon cancer progression via forming a positive
feedback loop with PCDH7. Mol Ther Nucleic Acids. 20:545–557. 2020.
View Article : Google Scholar : PubMed/NCBI
|
